Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 2, 2006, Pages 384-391

  Jang, Jeong Won ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Kim, Chang Wook ^a   Han, Nam Ik ^a   Han, Jun Yeol ^a   Choi, Sang Wook ^a   Yoon, Seung Kew ^a   Chung, Kyu Won ^a   Sun, Hee Sik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

HBeAg; Hepatitis B virus; Lamivudine; Relapse

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION; RETREATMENT; SEROCONVERSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS RESISTANCE;

EID: 33645232898     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04035.x     Document Type: Article

References (15)

1. Lee WM Hepatitis B virus infection NEnglJMed 1997 337 1733 45
2. Dienstag JL Schiff ER Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy Hepatology 1999 30 1082 7
3. Lee KM Cho SW Kim SW Kim HJ Hahm KB Kim JH Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion JViralHepat 2002 9 208 12
4. Song BC Suh DJ Lee HC Chung YH Lee YS Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 2000 32 803 6
5. Lee CM Ong GY Lu SN et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation JHepatol 2002 37 669 74
6. Dienstag JL Cianciara J Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 2003 37 748 55
7. Ryu SH Chung YH Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study JHepatol 2003 39 614 19
8. Kato H Ruzibakiev R Yuldasheva N et al. Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping JMedVirol 2002 67 477 83
9. Allen MI Gauthier J DesLauriers M et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine JClinMicrobiol 1999 37 3338 47
10. Hsu YS Chien RN Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 2002 35 1522 7
11. Niederau C Heintges T Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B NEnglJMed 1996 334 1422 7
12. Chien RN Liaw YF Atkins M Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B Hepatology 1999 30 770 4
13. Leung NW Lai CL Chang TT Asia Hepatitis Lamivudine Study Group et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 2001 33 1527 32
14. Nafa S Ahmed S Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B Hepatology 2000 32 1078 88
15. Tassopoulos NC Volpes R Pastore G et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Hepatology 1999 29 889 96